Clinical Trials Directory

Trials / Completed

CompletedNCT03611491

Post Market Study Evaluating Princess Filler Lidocaine for the Correction of Nasolabial Folds

A Prospective, Open Label, Multicenter, Post Market Study Evaluating Princess® FILLER Lidocaine for the Correction of Nasolabial Folds

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
60 (actual)
Sponsor
Croma-Pharma GmbH · Industry
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

In this study, eligible subjects with moderate to severe nasolabial folds will be treated with Princess® FILLER Lidocaine and will return for follow-up assessments 2, 4, 24 and 36 weeks after the treatment. A Touch-up treatment may be done at Week 2, if deemed appropriate by the investigator

Detailed description

A prospective, open label, multicenter, post-market investigation. Following informed consent and screening, eligible subjects with moderate to severe nasolabial folds were treated with Princess® FILLER Lidocaine, and were to return for follow-up assessments 2, 4, 24 and 36 weeks after the initial treatment. A Touch-up treatment may be done at Week 2 after initial treatment, if deemed appropriate by the investigator. The performance of the investigational device evaluated by the investigator by assessing severity of nasolabial folds using the Nasolabial Folds Severity Rating Scale (NLF-SRS) (4, 24 and 36 weeks after the initial treatment and in comparison to Day 0) and global aesthetic improvement (4, 24 and 36 weeks after the initial treatment). The subject evaluated pain intensity associated with the treatment (at Day 0 and at Week 2 after initial treatment (if Touch-up treatment occurred)), and satisfaction with the treatment 4, 24 and 36 weeks after the initial treatment. The safety was evaluated based on occurrence of adverse events, which were collected throughout the investigation.

Conditions

Interventions

TypeNameDescription
DEVICEPrincess FILLER LidocainePrincess FILLER Lidocaine injection up to 10 ml given to the patients at baseline time point. After 2 week a touch up is given in case to be consider necessary.

Timeline

Start date
2017-09-20
Primary completion
2018-11-19
Completion
2018-11-19
First posted
2018-08-02
Last updated
2025-03-18
Results posted
2025-03-18

Locations

2 sites across 1 country: Austria

Source: ClinicalTrials.gov record NCT03611491. Inclusion in this directory is not an endorsement.